Sugi Predict

Sugi Predict / Compounds / SCHEMBL47340

SCHEMBL47340

SCHEMBL47340

C[C@@H](c1cccc(O)c1)N(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB1 P08588 2/20 0.53
▸ ADRA1A P35348 2/20 0.53
▸ MIF P14174 1/20 0.53
▸ HTR2A P28223 1/20 0.53
▸ HTR2B P41595 1/20 0.53
▸ ACHE P22303 4/20 0.51
▸ OPRM1 P35372 2/20 0.51
▸ SLC22A1 O15245 1/20 0.51
▸ SLC6A3 Q01959 2/20 0.49
▸ SLC6A4 P31645 1/20 0.49
▸ KDR P35968 1/20 0.49
▸ BCHE P06276 2/20 0.47
▸ TSHR P16473 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ FAAH O00519 1/20 0.46
▸ OPRK1 P41145 2/20 0.46
▸ HIF1A Q16665 4/20 0.46
▸ ADRB2 P07550 1/20 0.46
▸ HTR1A P08908 1/20 0.46
▸ ADRA2A P08913 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12557215 1.00 ADRB1 (0.53) ADRB1ADRA1AMIFHTR2AHTR2B
SCHEMBL27858675 1.00 ADRB1 (0.53) ADRB1ADRA1AMIFHTR2AHTR2B
SCHEMBL29809913 1.00 ADRB1 (0.53) ADRB1ADRA1AMIFHTR2AHTR2B
SCHEMBL43343 1.00 ADRB1 (0.53) ADRB1ADRA1AMIFHTR2AHTR2B
SCHEMBL27858674 1.00 ADRB1 (0.53) ADRB1ADRA1AMIFHTR2AHTR2B
Hydrochloric Acid SCHEMBL4060357 0.98 ADRB1 (0.52) ADRB1ADRA1AMIFHTR2AHTR2B
SCHEMBL3274216 0.89 OPRM1 (0.57) ADRB1ADRA1AMIFHTR2AHTR2B
Methylethylamine SCHEMBL5320200 0.88 HIF1A (0.53) ADRB1ADRA1AMIFHTR2AHTR2B
Propylamine SCHEMBL5320197 0.88 OPRM1 (0.50) ADRB1ADRA1AMIFHTR2AHTR2B
SCHEMBL13310383 0.85 OPRM1 (0.54) ADRB1ADRA1AMIFHTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230172895-A1 METHODS OF TREATING OR PREVENTING ORGANOPHOSPHORUS POISONING LACHESIS BIOSCIENCES LIMITED (AU) 2023-06-08 — — US claimed
EP-4171542-A1 METHODS OF TREATING OR PREVENTING ORGANOPHOSPHORUS POISONING Lachesis Biosciences Limited (AU) 2023-05-03 — — EP claimed
CN-106565543-B A kind of preparation method of rivastigmine-hydrogentartrate 昆明源瑞制药有限公司 2018-06-22 — — CN claimed
CN-107334740-A For stable rivastigmine-hydrogentartrate piece of fortified phenol and preparation method thereof 万全万特制药江苏有限公司 2017-11-10 — — CN claimed
CN-106565543-A Preparation method of rivastigmine tartrate 昆明源瑞制药有限公司 2017-04-19 — — CN claimed
EP-1856036-B1 AN EFFICIENT METHOD FOR PREPARATION OF (S)-3-[(1-DIMETHYL AMINO)ETHYL]-PHENYL-N-ETHYL-N-METHYL-CARBAMATE EMCURE PHARMACEUTICALS LTD (IN) 2016-12-14 — — EP claimed
CN-104151176-B A kind of Rivastigmine chiral intermediate and preparation method thereof 大连韦德生化科技有限公司 2016-08-24 — — CN claimed
CN-103193600-B The preparation method of rivastigmine intermediate ZHEJIANG JIUZHOU PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2016-04-06 — — CN claimed
CN-104151176-A Chiral intermediate of rivastigmine, and preparation method thereof DALIAN WONDERSUN BIOCHEMICAL TECHNOLOGY CO LTD 2014-11-19 — — CN claimed
US-8637713-B2 Process for preparation of optically active compounds using transfer hydrogenation NOVARTIS AG (CH) 2014-01-28 — — US claimed
CN-102264672-A Process for preparing optically active compounds using transfer hydrogenation — 2011-11-30 — — CN claimed
EP-2382172-A1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE COMPOUNDS USING TRANSFER HYDROGENATION Novartis AG (CH) 2011-11-02 — — EP claimed
US-8013181-B2 Reacting S-(-)-[1-(3-hydroxyphenyl)ethyl]dimethylamine with N-ethyl-N-methyl carbamoyl chloride in the presence of an organic base DR. REDDY'S LABORATORIES LIMITED (IN) 2011-09-06 — — US claimed
WO-2011073362-A1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE COMPOUNDS USING PRESSURE HYDROGENATION NOVARTIS AG (CH) 2011-06-23 — — WO claimed
WO-2010072798-A1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE COMPOUNDS USING TRANSFER HYDROGENATION NOVARTIS AG (CH) 2010-07-01 — — WO claimed
US-20100168229-A1 Process for the preparation of optically active compounds using transfer hydrogenation NOVARTIS AG (CH) 2010-07-01 — — US claimed
CN-101613292-A (S)-preparation method of 3-(1-dimethylaminoethyl) phenol SHANGHAI PHARMACEUTICAL GROUP 2009-12-30 — — CN claimed
US-20080255383-A1 PREPARATION OF RIVASTIGMINE AND ITS SALTS DR. REDDY'S LABORATORIES, INC. 2008-10-16 — — US claimed
EP-1980552-A2 A process for the preparation of rivastigmine or a salt thereof Dr. Reddy's Laboratories Ltd. (IN) 2008-10-15 — — EP claimed
CN-1486973-A Ethyl methyl 3-[(1s)-1-(dimethylamino) ethyl] phenyl carbamate and its prepn and medicine use 上海三维制药有限公司 2004-04-07 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168229-A1 Process for the preparation of optically active compounds using transfer hydrogenation SPR, ACHE, QDPR ADRB1 549/4885ADRA1A 723/4885MIF 4039/4885
US-20230172895-A1 METHODS OF TREATING OR PREVENTING ORGANOPHOSPHORUS POISONING ACHE, BCHE, CHRM3 ADRB1 1358/4885ADRA1A 1275/4885MIF 4230/4885
US-20080255383-A1 PREPARATION OF RIVASTIGMINE AND ITS SALTS ACHE, EHMT1, BCHE ADRB1 1993/4885ADRA1A 1659/4885MIF 3499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.